FORMULATIONS INCLUDING 5-[3-(3-HYDROXYPHENOXY)AZETIDIN-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE
Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or a pharmaceutically accep...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
03.05.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or a pharmaceutically acceptable salt thereof and an excipient. Another powder formulation includes in addition to the carboxamide compound or its hydrochloride salt a long acting β2 adrenoreceptor agonist and an inhalable corticosteroid. |
---|---|
Bibliography: | Application Number: EP20210773142 |